Abstract 1913P
Background
Transbronchial microwave lung ablation has been a novel local therapy for early lung cancers and lung oligometastases, especially in patients who have high surgical risks or suffer from multifocal lung tumours. This is a single institute retrospective review of the 5-year result of transbronchial microwave ablation using electromagnetic navigation bronchoscopy guidance in the hybrid operating room.
Methods
Between March 2019 and March 2024, 223 nodules in 145 patients were treated. Eligible lung nodules were either proven lung cancers, metastases, or radiologically suspicious. Safety and mid-term control rate of the technique were assessed.
Results
Mean maximal diameter of lung nodules was 11.8mm (range 6-29mm), and bronchus sign was positive in only 24.7% of them. Technical success rate was 100%, although 104 (46.6%) nodules required double ablation and 25 (11.2%) required triple or more ablation for adequate coverage. Mean minimal ablation margin was 6.3mm. Concomitant lung resection for other nodules was performed in 16 cases. Mean hospital stay was 1.56 days, 172 cases (77.1%) and 214 cases (95.9%) were discharged by post-ablation day 1 and 3 respectively. Complications included mild pain which did not require hospitalization (6.7%), pneumothorax requiring drainage (3.6%), hemoptysis (2.7%), post-ablation reaction (2.2%) and pleural effusion (1.8%). Mean follow up for all cases is 25.3 months. Thirteen cases of local ablation site recurrence (5.8%) have been identified, which were treated by re-ablation, stereotactic radiation therapy or surgery.
Conclusions
Transbronchial microwave ablation is a safe and novel ablative technique, and has encouraging mid-term local control rate.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Research Grants Council (RGC) University Grant Committee Hong Kong, no: 14119019.
Disclosure
R. Lau: Financial Interests, Personal, Advisory Board: Medtronic. C. Ng: Financial Interests, Institutional, Speaker, Consultant, Advisor: Johnson and Johnson, Medtronic, USA, Siemens Healthineer. All other authors have declared no conflicts of interest.
Resources from the same session
1514P - A prospective, single-center, randomized, controlled, evaluator-blinded, feasibility clinical trial for efficacy and safety of a non-tissue destructive compact focused ultrasound system with neoadjuvant FOLFIRINOX in locally advanced or borderline resectable pancreatic cancer
Presenter: Jae Young Lee
Session: Poster session 18
1515P - Surgery versus chemotherapy for pulmonary oligometastasis after pancreatectomy: A multicentre observational study
Presenter: Ryoji Takada
Session: Poster session 18
1516P - Lung-only metastatic PDAC: Another disease?
Presenter: Léa Mercier
Session: Poster session 18
1517P - Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study
Presenter: Giulia Orsi
Session: Poster session 18
1518P - Stereotactic radiotherapy and IMM-101 in patients with oligometastatic pancreatic cancer following FOLFIRINOX: The MEPANC trial
Presenter: Leonoor Wismans
Session: Poster session 18
Resources:
Abstract
1519P - Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study
Presenter: Makoto Ueno
Session: Poster session 18
1520P - Real-world assessment of NALIRIFOX for advanced pancreatic ductal adenocarcinoma: An exploratory analysis
Presenter: Andreas Reichinger
Session: Poster session 18
Resources:
Abstract
1521P - Efficacy and safety of liposomal irinotecan plus S-1 in patients with metastatic pancreatic cancer after failure of first-line gemcitabine-based chemotherapy: Result of a phase I/II study
Presenter: Hiroshi Imaoka
Session: Poster session 18
1522P - S-1 monotherapy versus nanoliposomal irinotecan plus 5-fluorouracil/leucovorin regimen for second-line therapy of recurrent or metastatic pancreatic cancer (JON 2109-P)
Presenter: Yuichiro Tozuka
Session: Poster session 18
1523P - Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Presenter: Yasin Sezgin
Session: Poster session 18